Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29389718 | 1.00 | KDM4E (0.67) | KDM4EALDH1A1MAPTRAB9ANPSR1 | |
| SCHEMBL22388821 | 0.85 | KDM4E (0.71) | KDM4EALDH1A1MAPTRAB9ANPSR1 | |
| SCHEMBL29389712 | 0.85 | KDM4E (0.71) | KDM4EALDH1A1MAPTRAB9ANPSR1 | |
| SCHEMBL12905299 | 0.83 | KDM4E (0.69) | KDM4EALDH1A1MAPTRAB9ANPSR1 | |
| SCHEMBL4409652 | 0.82 | POLB (0.63) | KDM4EALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL23961083 | 0.81 | ALDH1A1 (0.67) | KDM4EALDH1A1MAPTRAB9ANPSR1 | |
| SCHEMBL12905316 | 0.81 | KDM4E (0.67) | KDM4EALDH1A1MAPTRAB9ANPSR1 | |
| SCHEMBL19359241 | 0.79 | ALDH1A1 (0.63) | KDM4EALDH1A1MAPTRAB9ANPSR1 | |
| SCHEMBL12896373 | 0.79 | MAPT (0.63) | KDM4EALDH1A1MAPTRAB9ANPSR1 | |
| SCHEMBL6693868 | 0.79 | KMT2A (1.00) | KDM4EALDH1A1MAPTRAB9ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241241-A1 | CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230241241-A1 | CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230115871-A1 | A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2023-04-13 | — | — | US | disclosed |
| US-20230057350-A1 | A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-02-23 | — | — | US | disclosed |
| CN-115443134-A | Conjugates of cell binding molecules and camptothecin analogs | 杭州多禧生物科技有限公司 | 2022-12-06 | — | — | CN | disclosed |
| CN-114040779-A | Conjugates of cell binding molecules containing branched linkers and cytotoxic agents | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | disclosed |
| WO-2021212638-A1 | CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-10-28 | — | — | WO | disclosed |
| CN-113423430-A | Amanitoxin conjugates containing branched linkers | 杭州多禧生物科技有限公司 | 2021-09-21 | — | — | CN | disclosed |
| WO-2020257998-A1 | A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2020-12-30 | — | — | WO | disclosed |
| US-20200276261-A1 | A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2020-09-03 | — | — | US | disclosed |
| WO-2020155017-A1 | A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230057350-A1 | A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS | BTN3A1, ANTXR2, CLTA | KDM4E 4187/4885ALDH1A1 4011/4885MAPT 1235/4885 |
| US-20230115871-A1 | A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS | CD2BP2, EPCAM, CD74 | KDM4E 4343/4885ALDH1A1 2397/4885MAPT 3834/4885 |
| US-20200276261-A1 | A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | TEKT1, TEK, BTN3A1 | KDM4E 3978/4885ALDH1A1 4604/4885MAPT 2764/4885 |
| US-20230241241-A1 | CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS | CD4, DCLRE1A, TOP1 | KDM4E 4137/4885ALDH1A1 3405/4885MAPT 3691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.